Ultimate Sensitivity
Redefines the state-of-the-art sensitivity (LOD) for important TBI and AD protein biomarkers.
AperionDx develops innovative diagnostic solutions that make protein detection more sensitive, more reliable*, faster and effortlessly scalable.
What We Do
AperionDx leverages Protein-PCR™ technology on existing qPCR instruments, creating a global protein-measurement network with minimal setup, no new hardware, and easy rollout.
Why Protein-PCR™?
Redefines the state-of-the-art sensitivity (LOD) for important TBI and AD protein biomarkers.
Runs on widely available qPCR systems; no proprietary hardware required.
Detects multiple key biomarkers in a single well via a cost-effective workflow.
Designed to complement imaging and Cerebrospinal Fluid (CSF) assays.
High-throughput testing for research and clinical settings with < 4-hour Turnaround Time.
The Workflow
Measure full panels of disease-specific biomarkers from blood samples at extremely low concentrations.
Compatible with 96- and 384-well plates, allowing processing of up to 350 samples per run.
Turnaround Time (TAT) in under four hours.
By the Numbers
Years combined experience
Government funding secured
Successful exits
Patents
Use Cases
*Pending regulatory review
Next step
Need customized, ultra-sensitive diagnostic tests for specific protein biomarkers essential for drug or therapeutic development? Call AperionDx.